PATH and Sinapi Biomedical, South Africa, developed the first low-cost, fully assembled uterine balloon tamponade device to help protect women from the leading cause of maternal death, post-partum hemorrhage. The Ellavi UBT is preassembled device used in multiple countries to manage postpartum hemorrhage.

In 2020, Harvard University researcher, Elizabeth Pylant Bransford Maxwell, authored a study: "A Comparative Analysis of User Experience With Uterine Balloon Devices During Standardized Postpartum Hemorrhage Simulations" which showed the Ellavi UBT to be the "simplest, easiest, and fastest device to use overall."